PROCEPT BioRobotics Corporation (PRCT)
Market Cap | 2.19B |
Revenue (ttm) | 274.95M |
Net Income (ttm) | -84.15M |
Shares Out | 55.33M |
EPS (ttm) | -1.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,918,652 |
Open | 42.00 |
Previous Close | 45.69 |
Day's Range | 37.12 - 42.52 |
52-Week Range | 37.12 - 103.81 |
Beta | 1.04 |
Analysts | Buy |
Price Target | 75.57 (+90.88%) |
Earnings Date | Aug 6, 2025 |
About PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign p... [Read more]
Financial Performance
In 2024, PROCEPT BioRobotics's revenue was $224.50 million, an increase of 64.84% compared to the previous year's $136.19 million. Losses were -$91.41 million, -13.68% less than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PRCT stock is "Buy." The 12-month stock price target is $75.57, which is an increase of 90.88% from the latest price.
News

PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Ma...

PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...

PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...

Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...

PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transfo...

Aquablation® Therapy's Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformat...

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solu...

PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, ...

PROCEPT BioRobotics Corporation (PRCT) Q1 2025 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations & Business Operations Rez...

PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transf...

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment global...

WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a randomiz...

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfo...

Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company's HYDROS robotic system and consumables busines...

PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfor...

PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
SAN JOSE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solut...

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)
NEW YORK--(BUSINESS WIRE)--Spruce Point Capital Management, LLC (“Spruce Point” or “we” or “us”), a New York-based investment management firm that focuses on forensic research and short-selling, today...

PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solu...

Procept BioRobotics: Continued Growth Runway Ahead
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and op...

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient c...

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient c...

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Exec...

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transfor...